In entering into a distribution agreement with Kindstar Globalgene Technology (Beijing, China), Wren Laboratories has expanded the global availability of our molecular neuroendocrine cancer diagnostic, the NETest. This partnership will double NETest utilization in 2024, providing oncologists for 300,000 NET cancer patients in China the ability to better understand their patient’s tumor status and monitor therapy progression.
Recent Comments